Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GNBT>>>Starting to rebound right now...this is a multi bagger in the making. Company is going to be on Bloomberg TV this coming Monday!
http://finance.yahoo.com/news/Breast-Cancer-Vaccine-Being-prnews-2837270956.html?x=0
GNBT>>>The closer we get to Monday's Bloomberg exposure, the higher the PPS will go. Jump in NOW!!!
"Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television
Vaccine Also Referenced in Newsweek Magazine"
http://finance.yahoo.com/news/Breast-Cancer-Vaccine-Being-prnews-2837270956.html?x=0
GNBT>>>The closer we get to Monday's Bloomberg exposure, the higher the PPS will go. Jump in NOW!!!
"Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television
Vaccine Also Referenced in Newsweek Magazine"
http://finance.yahoo.com/news/Breast-Cancer-Vaccine-Being-prnews-2837270956.html?x=0
GNBT>>>From Yahoo board of GNBT. Please read it!
"SHOW TIME "2" = + 100% 14-Dec-11 06:43 am
Friends, Romans, Countrymen and Shareowners. For a second time in one (1) week , on 12/14/2011 “MarketClub's Trade Triangle” technology. Has given GENEREX [GNBT] a rating of…=…+100 %, folks this is very rare, a very powerful sign, your guess is as good as mine. However this also means in the Wall Street lingo, that some very powerful entities are aware of certain very positive info. Also, in the last 2 weeks the under the same rating agency, the score given and holding was + 80 % or better....Again, what’s happening baby ?...I guess we'll all have to wait for the next curtain to rise !...P/S, FINAL ACT ?
GNBT>>>From Yahoo board of GNBT. Please read it!
"SHOW TIME "2" = + 100% 14-Dec-11 06:43 am
Friends, Romans, Countrymen and Shareowners. For a second time in one (1) week , on 12/14/2011 “MarketClub's Trade Triangle” technology. Has given GENEREX [GNBT] a rating of…=…+100 %, folks this is very rare, a very powerful sign, your guess is as good as mine. However this also means in the Wall Street lingo, that some very powerful entities are aware of certain very positive info. Also, in the last 2 weeks the under the same rating agency, the score given and holding was + 80 % or better....Again, what’s happening baby ?...I guess we'll all have to wait for the next curtain to rise !...P/S, FINAL ACT ?
GNBT>>>On Bloomberg TV this coming Monday, Can you say Kaboom!!!
Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television
Vaccine Also Referenced in Newsweek Magazine
WORCESTER, Mass. and TORONTO, Dec. 14, 2011 /PRNewswire via COMTEX/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that Bloomberg Television will air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc.
The story, expected to air December 19, 2011, will cover the Company's novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37), which is the subject of an ongoing Phase 2 clinical study in patients with HER-2 expressing breast cancer. The segment will be featured in Bloomberg's "Innovators" segment, which focuses on world-changing technologies and innovations.
Positive interim results from the ongoing Phase 2 study of AE37 were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) earlier this month. Final Phase 2 results are expected in 2012.
The segment will include an interview by Bloomberg reporter Cali Carlin of Dr. Eric von Hofe, Ph.D., President of Antigen Express, and COL George E. Peoples, MD, FACS, Director, Cancer Vaccine Development Program.
"Development of the Antigen Express immunotherapeutic vaccine technologies has progressed to the point where people are beginning to take notice," commented Mark Fletcher, President & Chief Executive Officer of Generex. "This Bloomberg piece follows on the heels of the SABCS presentation and the reference to the breast cancer vaccine in Newsweek magazine on December 12, 2011 in science columnist and science editor Sharon Begley's article, Could This Be The End of Cancer? (http://www.thedailybeast.com/newsweek/2011/12/11/could-this-be-the-end-of-cancer.html)."
About AE37 and Ii-Key Hybrid Platform Technology
Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.
The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37). This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.
About Breast Cancer
According to the American Cancer Society, more than 232,000 women will be diagnosed with breast cancer, and nearly 40,000 will die from the disease, in 2011. For women whose cancer tests positive for increased quantities of the HER2, approved targeted therapies include trastuzumab (Herceptin?; Roche-Genentech). However, only 25% of breast cancer patients have HER2 levels high enough to be eligible for Herceptin. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER2 expression.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
GNBT>>>On Bloomberg TV this coming Monday, Can you say Kaboom!!!
Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television
Vaccine Also Referenced in Newsweek Magazine
WORCESTER, Mass. and TORONTO, Dec. 14, 2011 /PRNewswire via COMTEX/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that Bloomberg Television will air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc.
The story, expected to air December 19, 2011, will cover the Company's novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37), which is the subject of an ongoing Phase 2 clinical study in patients with HER-2 expressing breast cancer. The segment will be featured in Bloomberg's "Innovators" segment, which focuses on world-changing technologies and innovations.
Positive interim results from the ongoing Phase 2 study of AE37 were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) earlier this month. Final Phase 2 results are expected in 2012.
The segment will include an interview by Bloomberg reporter Cali Carlin of Dr. Eric von Hofe, Ph.D., President of Antigen Express, and COL George E. Peoples, MD, FACS, Director, Cancer Vaccine Development Program.
"Development of the Antigen Express immunotherapeutic vaccine technologies has progressed to the point where people are beginning to take notice," commented Mark Fletcher, President & Chief Executive Officer of Generex. "This Bloomberg piece follows on the heels of the SABCS presentation and the reference to the breast cancer vaccine in Newsweek magazine on December 12, 2011 in science columnist and science editor Sharon Begley's article, Could This Be The End of Cancer? (http://www.thedailybeast.com/newsweek/2011/12/11/could-this-be-the-end-of-cancer.html)."
About AE37 and Ii-Key Hybrid Platform Technology
Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.
The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37). This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.
About Breast Cancer
According to the American Cancer Society, more than 232,000 women will be diagnosed with breast cancer, and nearly 40,000 will die from the disease, in 2011. For women whose cancer tests positive for increased quantities of the HER2, approved targeted therapies include trastuzumab (Herceptin?; Roche-Genentech). However, only 25% of breast cancer patients have HER2 levels high enough to be eligible for Herceptin. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER2 expression.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
AQLV>>>Starting to take off...just like Friday!!!
AQLV>>>Starting to take off...just like Friday!!!
AQLV>>>Train is leaving the station...MULTI BAGGER in the making!!! IMO
AQLV>>>>KABOOM!!!!
No trades right now, and the bids are going up. I like it!
Another wave is coming, except this one is going to be a Tsunami!!!
AQLV>>>Monster in the making!
AQLV>>>Monster in the making!
AQLV>>> .01 here it comes!
AQLV>>>Buys are pouring in right now...something is up!
AQLV>>>Buys are pouring in right now...something is up!
AQLV>>>The train is leaving the station!
There is no doubt in my mind that this stock will be at a .01 shortly!
easy ten bagger in the short run! IMO
10 million shares trade was between Market Makers!
ALCL>>>Next monster mover! IMO
ALCL>>>Next monster mover! IMO
ALCL>>>Take a look at this chart...what a buy! Stock is at .0046 right now, this one is a no brainer.
ALCL>>>Take a look at this chart...what a buy! Stock is at .0046 right now, this one is a no brainer.
ALCL>>>This one can do EUOTD's huge spike...Way oversold!!!
ALCL>>>This one can do EUOTD's huge spike...Way oversold!!!
AERN>>>Rebounding hard right now...something is up!
AERN>>>Rebounding hard right now...something is up!
AERN>>>Making a huge move upwards right now. Looks like it will close at high of the day.
AERN>>>Making a huge move upwards right now. Looks like it will close at high of the day.
AERN>>>Second wave is coming now!
AERN>>>Volume is crazy, needs to break .04 and we are off to the races!
AERN>>>Volume is crazy, needs to break .04 and we are off to the races!
AERN>>>Huge momentum is back, .10 possible by tomorrow, .15 to .20 next week. IMO
http://www.baystreet.ca/articles/research_reports/Cohen/aern-report.pdf
AERN>>>Huge momentum is back, .10 possible by tomorrow, .15 to .20 next week. IMO
http://www.baystreet.ca/articles/research_reports/Cohen/aern-report.pdf
AERN>>>Back to .20 cents or higher in the short run! IMHO
http://www.baystreet.ca/articles/research_reports/Cohen/aern-report.pdf
AERN>>>Back to .20 cents or higher in the short run! IMHO
http://www.baystreet.ca/articles/research_reports/Cohen/aern-report.pdf
AERN>>>Check this...
http://www.baystreet.ca/articles/research_reports/Cohen/aern-report.pdf